share_log

科濟藥業-B：自願公告 - 於2024年ASCO年會上口頭報告CT041試驗數據更新

CARSGEN-B: VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION OF RESEARCH UPDATES ON SATRICABTAGENE AUTOLEUCEL AT 2024 ASCO ANNUAL MEETING

香港交易所 ·  Apr 11 06:25
Summary by Moomoo AI
科濟藥業-B（「本公司」）宣佈，其開發的CT041臨床試驗數據將於2024年美國臨床腫瘤學會（ASCO）年會上進行口頭報告。CT041是一種針對Claudin18.2蛋白的自體CAR-T細胞候選產品，主要用於治療胃癌、食管胃結合部腺癌及胰腺癌。此次報告的摘要將於2024年5月23日公佈，而口頭報告將於同年6月3日進行。CT041已在中國和北美開展多項臨床試驗，並已獲得美國FDA的「再生醫學先進療法」認定及歐洲藥品管理局的「優先藥品」資格。科濟藥業專注於CAR-T細胞療法，旨在提高治療安全性、效果及降低成本，致力於成為全球生物製藥的領導者。
科濟藥業-B（「本公司」）宣佈，其開發的CT041臨床試驗數據將於2024年美國臨床腫瘤學會（ASCO）年會上進行口頭報告。CT041是一種針對Claudin18.2蛋白的自體CAR-T細胞候選產品，主要用於治療胃癌、食管胃結合部腺癌及胰腺癌。此次報告的摘要將於2024年5月23日公佈，而口頭報告將於同年6月3日進行。CT041已在中國和北美開展多項臨床試驗，並已獲得美國FDA的「再生醫學先進療法」認定及歐洲藥品管理局的「優先藥品」資格。科濟藥業專注於CAR-T細胞療法，旨在提高治療安全性、效果及降低成本，致力於成為全球生物製藥的領導者。
KOCHI PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCED THAT ITS DEVELOPED CT041 CLINICAL TRIAL DATA WILL BE REPORTED ORALLY AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) IN 2024. CT041 is an autologous CAR-T cell candidate for Claudin18.2 protein that is primarily used in the treatment of gastric cancer, gastroesophageal combined prostate cancer and pancreatic cancer. The summary of this report will be published on 23 May 2024 and the oral report will be made on 3 June of the same year. CT041 has been conducted in several clinical trials in China and North America and has been recognized as a “Regenerative Medicine Advanced Therapeutics” by the US FDA and a “Preferred Drug” status by the European Medicines Agency. With a focus on CAR-T cell therapy, Kozin Pharmaceuticals aims to be a global leader in biopharmaceuticals to improve treatment safety, efficacy and lower costs.
KOCHI PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCED THAT ITS DEVELOPED CT041 CLINICAL TRIAL DATA WILL BE REPORTED ORALLY AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) IN 2024. CT041 is an autologous CAR-T cell candidate for Claudin18.2 protein that is primarily used in the treatment of gastric cancer, gastroesophageal combined prostate cancer and pancreatic cancer. The summary of this report will be published on 23 May 2024 and the oral report will be made on 3 June of the same year. CT041 has been conducted in several clinical trials in China and North America and has been recognized as a “Regenerative Medicine Advanced Therapeutics” by the US FDA and a “Preferred Drug” status by the European Medicines Agency. With a focus on CAR-T cell therapy, Kozin Pharmaceuticals aims to be a global leader in biopharmaceuticals to improve treatment safety, efficacy and lower costs.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more